Вопросы гематологии/онкологии и иммунопатологии в педиатрии. 2025; 24: 207-215
Опыт и перспективы использования внутривенных препаратов железа в педиатрической практике
https://doi.org/10.24287/1726-1708-2025-24-1-207-215Аннотация
Во всем мире железодефицитная анемия приводит к медицинским и социальным последствиям, поэтому лечение дефицита железа является важной задачей. Применение пероральных препаратов железа не всегда оказывается оптимальным в клинической ситуации, требующей быстрого восполнения запасов железа, или в связи с возможной неэффективностью или непереносимостью. Внутривенная ферротерапия – эффективный метод лечения железодефицитной анемии. До настоящего времени применение внутривенных препаратов железа в педиатрической когорте ограничено, несмотря на большой опыт их использования у взрослых пациентов и результаты исследований у детей, доказавшие эффективность и безопасность данной терапевтической опции в этой популяции. Прежде всего, это связано с опасениями в отношении тяжелых аллергических реакций, риск которых был довольно высоким в эпоху использования первых препаратов железа для внутривенного введения. Появление весьма эффективного и более безопасного поколения препаратов железа для внутривенного введения, в том числе для высокодозной ферротерапии, делает привлекательным данный вид лечения дефицита железа у детей и подростков.
Список литературы
1. World Health Organization: WHO guidance helps detect iron deficiency and protect brain development 20 April 2020 News release. [Electronic resource] URL: https://www.who.int/publications-detail-redi-rect/9789240000124 (accessed 12.02.2025).
2. Safiri S., Kolahi A.A., Noori M., Nejadghaderi S.A., Karamzad N., Bragazzi N.L., et al. Burden of anemia and its underlying causes in 204 countries and territories, 1990– 2019: results from the Global Burden of Disease Study 2019. J Hematol Oncol 2021; 14: 185. DOI: 10.1186/s13045-021-01202-2
3. Городецкий В.В., Годулян О.В. Железодефицитные состояния и железодефицитная анемия: лечение и диагностика. М.; 2008. С. 1–27.
4. Анемии у детей: диагностика, дифференциальная диагностика, лечение. Под ред. А.Г. Румянцева и Ю.Н. Токарева. 2-е изд. доп. и перераб. М.; 2004. 216 с.
5. Powers J.M. Iron deficiency in infants and children < 12 years: Screening, prevention, clinical manifestations, and diagnosis 2024 Literature review current through: Nov 2024. This topic last updated: Jun 11, 2024. [Electronic resource] URL: https://www.uptodate.com/contents/iron-deficiency-in-infantsand-children-less-than12-yearstreatment? (accessed 12.02.2025).
6. Powers J.M. Iron requirements and iron deficiency in adolescents. This topic last updated: Jan 18, 2024. [Electronic resource] URL: https://www.uptodate.com/contents/iron-requirements-and-iron-deficiencyin-adolescents?search=iron%20requirements%20and%20iron%20deficiency%20in%20adolescents%20jacquelyn%20m%20powers&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1 (accessed 12.02.2025).
7. Лебедев В.В., Демихов В.Г., Лунякова М.А., Демихова Е.В., Носова Н.Ю. Дефицит железа и его влияние на поствакцинальный иммунитет. Педиатрия. Consilium Medicum 2024; 2: 254–9. DOI: 10.26442/26586630.2024.2.202896
8. Клинические рекомендации. Железодефицитная анемия. 2024. [Электронный ресурс] URL: https://cr.minzdrav.gov.ru/view-cr/669_2 (дата обращения 12.02.2025).
9. Achebe M., DeLoughery T.G. Clinical data for intravenous iron debunking the hype around hypersensitivity. Transfusion 2020; 60 (6): 1154–9. DOI: 10.1111/trf.15837
10. Meyer M.P., Haworth C., Meyer J.H., Commerford A. A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin. J Pediatr 1996; 129 (2): 258–63. DOI: 10.1016/s0022-3476(96)70251-2
11. [Electronic resource] URL: https://www.grls.minzdrav.gov.ru. (accessed 12.02.2025).
12. Mattiello V., Schmugge M., Hengartner H., von der Weid N., Renella R. SPOG Pediatric Hematology Working Group. Diagnosis and management of iron deficiency in children with or without anemia: consensus recommendations of the SPOG Pediatric Hematology Working Group. Eur J Pediatr 2020; 179: 527–45. DOI: 10.1007/s00431-020-03597-5
13. Mantadakis E., Chatzimichael E., Zikidou P. Iron deficiency anemia in children residing in high and low-income countries: risk factors, prevention, diagnosis and therapy. Mediterr J Hematol Infect Dis 2020; 12: e2020041. DOI: 10.4084/mjhid.2020.041
14. Aksan A., Zepp F., Anand S., Stein J. Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review. Eur J Pediatr 2022; 181 (11): 3781–93. DOI: 10.1007/s00431-022-04582-w
15. Domellöf M., Szitanyi P., Simchowitz V., Franz A., Mimouni F.; ESPGHAN/ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/ CSPEN guidelines on pediatric parenteral nutrition: iron and trace minerals. Clin Nutr 2018; 37 (6 Pt B): 2354––9. DOI: 10.1016/j.clnu.2018.06.949
16. Trenkwalder C., Stefani A., Bachmann C.G., Maihöfner C., Mathis J., Muntean L., et al. Restless legs syndrome: abbreviated guidelines by the German sleep society and the German neurological society. Neurol Res Pract 2024; 6: 53. DOI: 10.1186/s42466-024-00353-0
17. Демихов В.Г., Лебедев В.В., Демихова Е.В., Абаленихина Ю.В., Дмитриев А.В. Железодефицитные синдромы как основа персонифицированного подхода к лечению анемий в педиатрической практике. Педиатрия. Consilium Medicum 2020; 2: 80–4. [Demihov V.G.,
18. Andrews N.C. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004; 113 (9): 1251–3.
19. Bregman D.B., Morris D., Koch T.A., He A., Goodnough L.T. Hepcidin levels predict nonresponciveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 2013; 88 (2): 97–101. DOI: 10.1002/ajh.23354
20. Лунякова М.А., Демихов В.Г., Инякова Н.В., Райкина Е.В. Железорефрактерная железодефицитная анемия у детей: первые генетически подтвержденные случаи в России. Вопросы гематологии/ онкологии и иммунопатологии в педиатрии 2024; 23 (4): 138–43. DOI: 10.24287/1726-1708-2024-23-4-138-143
21. Tolkien Z., Stecher L., Mander A.P., Pereira D.I., Powell J.J. Ferrous sulfate supplementation causes significant gastrointestinal side‐effects in adults: a systematic review and meta‐analysis. PLoS One 2015; 10(2): e0117383.
22. DeLoughery T.G. Safety of Oral and Intravenous Iron. Acta Haematol 2019; 142 (1): 8–12. DOI: 10.1159/000496966
23. Richards T., Clevenger B., Keidan J., Collier T., Klein A.A., Anker S.D., et al. PREVENTT: preoperative intravenous iron to treat anaemia in major surgery: study protocol for a randomised controlled trial. Trials 2015; 16: 254. DOI: 10.1186/s13063-015-0774-2
24. Ng O., Keeler B.D., Mishra A., Simpson A., Neal K., Brookes M.J., Acheson A.G. Iron therapy for pre-operative anaemia. Cochrane Database Syst Rev 2015; (12): CD011588. DOI: 10.1002/14651858.CD011588.pub2
25. Camaschella C. Iron deficiency. Blood 2019; 133 (1): 30–9. DOI: 10.1182/blood-2018-05-815944
26. O'Lone E.L., Hodson E.M., Nistor I., Bolignano D., Webster A.C., Craig J.C. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2019; 2 (2): CD007857. DOI: 10.1002/14651858. CD007857.pub3
27. Goyal A., Zheng Y., Albenberg L.G., Stoner N.L., Hart L., Alkhouri R., et al. Anemia in children with inflammatory bowel disease: a position paper by the IBD Committee of the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2020; 71 (4): 563–82. DOI: 10.1097/MPG.0000000000002885
28. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2012; 2 (5): 339. DOI: 10.1038/kisup.2012.48
29. Fishbane S., Ungureanu V.D., Maesaka J.K., Kaupke C.J., Lim V., Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28 (4): 529–34. DOI: 10.1016/s0272-6386(96)90463-1
30. Bircher A.J., Auerbach M. Hypersensitivity from intravenous iron products. Immunol Allergy Clin North Am 2014; 34 (3): 707–23, x-xi. DOI: 10.1016/j.iac.2014.04.013
31. Rosano G., Schiefke I., Göhring U.M., Fabien V., Bonassi S., Stein J. A pooled analysis of serum phosphate measurements and potential hypophosphataemia events in 45 interventional trials with ferric carboxymaltose. J Clin Med 2020; 9 (11): 3587. DOI: 10.3390/jcm9113587
32. Hanif N., Anwer F. Chronic Iron Deficiency. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 Aug 8.
33. Avni T., Bieber A., Grossman A., Green H., Leibovici L., Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 2015; 90 (1): 12–23. DOI: 10.1016/j.mayocp.2014.10.007
34. Powers J.M., Shamoun M., McCavit T.L., Adix L., Buchanan G.R. Intravenous ferric carboxymaltose in children with iron deficiency anemia who respond poorly to oral iron. J Pediatr 2017; 180: 212–6 DOI: 10.1016/j.jpeds.2016.09.053
35. Gomollón F., Chowers Y., Danese S., Dignass A., Haagen Nielsen O., Lakatos P.L, et al. European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron containing medicines. European Medicines Agency 2013. Aliment Pharmacol Ther 2014; 39 (7): 743–4. DOI: 10.1111/apt.12648
36. Faich G., Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999; 33 (3): 464–70. DOI: 10.1016/s0272-6386(99)70183-6
37. Roganovic J. Parenteral iron therapy in children with iron deficiency anemia. World J Clin Cases 2024; 12 (13): 2138–42. DOI: 10.12998/wjcc.v12.i13.2138
38. Pinsk V., Levy J., Moser A., Yerushalmi B., Kapelushnik J. Efficacy and safety of intravenous iron sucrose therapy in a group of children with iron deficiency anemia. Isr Med Assoc J 2008; 10: 335–8.
39. Crary S.E., Hall K., Buchanan G.R. Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. Pediatr Blood Cancer 2011; 56: 615–9. DOI: 10.1002/pbc.22930
40. Kaneva K., Chow E., Rosenfield C.G., Kelly M.J. Intravenous iron sucrose for children with iron deficiency anemia. J Pediatr Hematol Oncol 2017; 39 (5): 259–62. DOI: 10.1097/MPH.0000000000000879
41. DelRosso L.M., Ferri R., Allen R.P., Chen M.L., Kotagal S., Picchietti D. 1001 intravenous ferric carboxymaltose for restless legs syndrome in children and adolescents. Sleep 2020; 43 (1): A380. DOI: 10.1093/sleep/zsaa056.997
42. DelRosso L.M., Picchietti D.L., Ferri R. Comparison between oral ferrous sulfate and intravenous ferric carboxymaltose in children with restless sleep disorder. Sleep 2021; 44: zsaa155. DOI: 10.1093/sleep/zsaa155
43. Bevers N., van de Vijver E., Aliu A., Rezazadeh Ardabili A., Rosias P., Busari J., et al. P398 effect of intravenous versus oral iron therapy on physical fitness and haemoglobin in paediatric IBD patients with anaemia. J Crohns Colitis 2021; 15 (l): 407–8. DOI: 10.1093/ecco-jcc/jjab076.522
44. Korczowski B., Farrell C., Falone M., Blackman N., Rodgers T. Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia. Pediatr Res 2023; 94 (4): 1547–54. DOI: 10.1038/s41390-023-02644-9
Pediatric Hematology/Oncology and Immunopathology. 2025; 24: 207-215
Experience and prospects of using intravenous iron preparations in pediatric practice
https://doi.org/10.24287/1726-1708-2025-24-1-207-215Abstract
Iron deficiency anemia has medical and social consequences worldwide, so the treatment of iron deficiency is an important goal. Oral iron therapy may not be optimal in some clinical situations requiring rapid replenishment of iron stores or due to possible ineffectiveness or intolerance. Intravenous iron therapy is an effective method for the treatment of iron deficiency anemia. So far, the use of intravenous iron preparations in pediatric patients has been limited, despite extensive experience of their use in adults and the results of studies conducted with children that have also demonstrated the efficacy and safety of this therapeutic option in pediatric patients. First of all, it is due to concerns about a risk of severe allergic reactions which was quite high in the era of first-generation intravenous iron medicines. The emergence of a new generation of more effective and safer intravenous iron preparations, including high-dose parenteral iron products, makes this type of therapy a promising means of treatment for iron deficiency in children and adolescents.
References
1. World Health Organization: WHO guidance helps detect iron deficiency and protect brain development 20 April 2020 News release. [Electronic resource] URL: https://www.who.int/publications-detail-redi-rect/9789240000124 (accessed 12.02.2025).
2. Safiri S., Kolahi A.A., Noori M., Nejadghaderi S.A., Karamzad N., Bragazzi N.L., et al. Burden of anemia and its underlying causes in 204 countries and territories, 1990– 2019: results from the Global Burden of Disease Study 2019. J Hematol Oncol 2021; 14: 185. DOI: 10.1186/s13045-021-01202-2
3. Gorodetskii V.V., Godulyan O.V. Zhelezodefitsitnye sostoyaniya i zhelezodefitsitnaya anemiya: lechenie i diagnostika. M.; 2008. S. 1–27.
4. Anemii u detei: diagnostika, differentsial'naya diagnostika, lechenie. Pod red. A.G. Rumyantseva i Yu.N. Tokareva. 2-e izd. dop. i pererab. M.; 2004. 216 s.
5. Powers J.M. Iron deficiency in infants and children < 12 years: Screening, prevention, clinical manifestations, and diagnosis 2024 Literature review current through: Nov 2024. This topic last updated: Jun 11, 2024. [Electronic resource] URL: https://www.uptodate.com/contents/iron-deficiency-in-infantsand-children-less-than12-yearstreatment? (accessed 12.02.2025).
6. Powers J.M. Iron requirements and iron deficiency in adolescents. This topic last updated: Jan 18, 2024. [Electronic resource] URL: https://www.uptodate.com/contents/iron-requirements-and-iron-deficiencyin-adolescents?search=iron%20requirements%20and%20iron%20deficiency%20in%20adolescents%20jacquelyn%20m%20powers&source=search_result&selectedTitle=1%7E150&usage_type=default&display_rank=1 (accessed 12.02.2025).
7. Lebedev V.V., Demikhov V.G., Lunyakova M.A., Demikhova E.V., Nosova N.Yu. Defitsit zheleza i ego vliyanie na postvaktsinal'nyi immunitet. Pediatriya. Consilium Medicum 2024; 2: 254–9. DOI: 10.26442/26586630.2024.2.202896
8. Klinicheskie rekomendatsii. Zhelezodefitsitnaya anemiya. 2024. [Elektronnyi resurs] URL: https://cr.minzdrav.gov.ru/view-cr/669_2 (data obrashcheniya 12.02.2025).
9. Achebe M., DeLoughery T.G. Clinical data for intravenous iron debunking the hype around hypersensitivity. Transfusion 2020; 60 (6): 1154–9. DOI: 10.1111/trf.15837
10. Meyer M.P., Haworth C., Meyer J.H., Commerford A. A comparison of oral and intravenous iron supplementation in preterm infants receiving recombinant erythropoietin. J Pediatr 1996; 129 (2): 258–63. DOI: 10.1016/s0022-3476(96)70251-2
11. [Electronic resource] URL: https://www.grls.minzdrav.gov.ru. (accessed 12.02.2025).
12. Mattiello V., Schmugge M., Hengartner H., von der Weid N., Renella R. SPOG Pediatric Hematology Working Group. Diagnosis and management of iron deficiency in children with or without anemia: consensus recommendations of the SPOG Pediatric Hematology Working Group. Eur J Pediatr 2020; 179: 527–45. DOI: 10.1007/s00431-020-03597-5
13. Mantadakis E., Chatzimichael E., Zikidou P. Iron deficiency anemia in children residing in high and low-income countries: risk factors, prevention, diagnosis and therapy. Mediterr J Hematol Infect Dis 2020; 12: e2020041. DOI: 10.4084/mjhid.2020.041
14. Aksan A., Zepp F., Anand S., Stein J. Intravenous ferric carboxymaltose for the management of iron deficiency and iron deficiency anaemia in children and adolescents: a review. Eur J Pediatr 2022; 181 (11): 3781–93. DOI: 10.1007/s00431-022-04582-w
15. Domellöf M., Szitanyi P., Simchowitz V., Franz A., Mimouni F.; ESPGHAN/ESPEN/ESPR/CSPEN working group on pediatric parenteral nutrition. ESPGHAN/ESPEN/ESPR/ CSPEN guidelines on pediatric parenteral nutrition: iron and trace minerals. Clin Nutr 2018; 37 (6 Pt B): 2354––9. DOI: 10.1016/j.clnu.2018.06.949
16. Trenkwalder C., Stefani A., Bachmann C.G., Maihöfner C., Mathis J., Muntean L., et al. Restless legs syndrome: abbreviated guidelines by the German sleep society and the German neurological society. Neurol Res Pract 2024; 6: 53. DOI: 10.1186/s42466-024-00353-0
17. Demikhov V.G., Lebedev V.V., Demikhova E.V., Abalenikhina Yu.V., Dmitriev A.V. Zhelezodefitsitnye sindromy kak osnova personifitsirovannogo podkhoda k lecheniyu anemii v pediatricheskoi praktike. Pediatriya. Consilium Medicum 2020; 2: 80–4. [Demihov V.G.,
18. Andrews N.C. Anemia of inflammation: the cytokine-hepcidin link. J Clin Invest 2004; 113 (9): 1251–3.
19. Bregman D.B., Morris D., Koch T.A., He A., Goodnough L.T. Hepcidin levels predict nonresponciveness to oral iron therapy in patients with iron deficiency anemia. Am J Hematol 2013; 88 (2): 97–101. DOI: 10.1002/ajh.23354
20. Lunyakova M.A., Demikhov V.G., Inyakova N.V., Raikina E.V. Zhelezorefrakternaya zhelezodefitsitnaya anemiya u detei: pervye geneticheski podtverzhdennye sluchai v Rossii. Voprosy gematologii/ onkologii i immunopatologii v pediatrii 2024; 23 (4): 138–43. DOI: 10.24287/1726-1708-2024-23-4-138-143
21. Tolkien Z., Stecher L., Mander A.P., Pereira D.I., Powell J.J. Ferrous sulfate supplementation causes significant gastrointestinal side‐effects in adults: a systematic review and meta‐analysis. PLoS One 2015; 10(2): e0117383.
22. DeLoughery T.G. Safety of Oral and Intravenous Iron. Acta Haematol 2019; 142 (1): 8–12. DOI: 10.1159/000496966
23. Richards T., Clevenger B., Keidan J., Collier T., Klein A.A., Anker S.D., et al. PREVENTT: preoperative intravenous iron to treat anaemia in major surgery: study protocol for a randomised controlled trial. Trials 2015; 16: 254. DOI: 10.1186/s13063-015-0774-2
24. Ng O., Keeler B.D., Mishra A., Simpson A., Neal K., Brookes M.J., Acheson A.G. Iron therapy for pre-operative anaemia. Cochrane Database Syst Rev 2015; (12): CD011588. DOI: 10.1002/14651858.CD011588.pub2
25. Camaschella C. Iron deficiency. Blood 2019; 133 (1): 30–9. DOI: 10.1182/blood-2018-05-815944
26. O'Lone E.L., Hodson E.M., Nistor I., Bolignano D., Webster A.C., Craig J.C. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2019; 2 (2): CD007857. DOI: 10.1002/14651858. CD007857.pub3
27. Goyal A., Zheng Y., Albenberg L.G., Stoner N.L., Hart L., Alkhouri R., et al. Anemia in children with inflammatory bowel disease: a position paper by the IBD Committee of the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2020; 71 (4): 563–82. DOI: 10.1097/MPG.0000000000002885
28. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2012; 2 (5): 339. DOI: 10.1038/kisup.2012.48
29. Fishbane S., Ungureanu V.D., Maesaka J.K., Kaupke C.J., Lim V., Wish J. The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 1996; 28 (4): 529–34. DOI: 10.1016/s0272-6386(96)90463-1
30. Bircher A.J., Auerbach M. Hypersensitivity from intravenous iron products. Immunol Allergy Clin North Am 2014; 34 (3): 707–23, x-xi. DOI: 10.1016/j.iac.2014.04.013
31. Rosano G., Schiefke I., Göhring U.M., Fabien V., Bonassi S., Stein J. A pooled analysis of serum phosphate measurements and potential hypophosphataemia events in 45 interventional trials with ferric carboxymaltose. J Clin Med 2020; 9 (11): 3587. DOI: 10.3390/jcm9113587
32. Hanif N., Anwer F. Chronic Iron Deficiency. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 Aug 8.
33. Avni T., Bieber A., Grossman A., Green H., Leibovici L., Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc 2015; 90 (1): 12–23. DOI: 10.1016/j.mayocp.2014.10.007
34. Powers J.M., Shamoun M., McCavit T.L., Adix L., Buchanan G.R. Intravenous ferric carboxymaltose in children with iron deficiency anemia who respond poorly to oral iron. J Pediatr 2017; 180: 212–6 DOI: 10.1016/j.jpeds.2016.09.053
35. Gomollón F., Chowers Y., Danese S., Dignass A., Haagen Nielsen O., Lakatos P.L, et al. European Medicines Agency. New recommendations to manage risk of allergic reactions with intravenous iron containing medicines. European Medicines Agency 2013. Aliment Pharmacol Ther 2014; 39 (7): 743–4. DOI: 10.1111/apt.12648
36. Faich G., Strobos J. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans. Am J Kidney Dis 1999; 33 (3): 464–70. DOI: 10.1016/s0272-6386(99)70183-6
37. Roganovic J. Parenteral iron therapy in children with iron deficiency anemia. World J Clin Cases 2024; 12 (13): 2138–42. DOI: 10.12998/wjcc.v12.i13.2138
38. Pinsk V., Levy J., Moser A., Yerushalmi B., Kapelushnik J. Efficacy and safety of intravenous iron sucrose therapy in a group of children with iron deficiency anemia. Isr Med Assoc J 2008; 10: 335–8.
39. Crary S.E., Hall K., Buchanan G.R. Intravenous iron sucrose for children with iron deficiency failing to respond to oral iron therapy. Pediatr Blood Cancer 2011; 56: 615–9. DOI: 10.1002/pbc.22930
40. Kaneva K., Chow E., Rosenfield C.G., Kelly M.J. Intravenous iron sucrose for children with iron deficiency anemia. J Pediatr Hematol Oncol 2017; 39 (5): 259–62. DOI: 10.1097/MPH.0000000000000879
41. DelRosso L.M., Ferri R., Allen R.P., Chen M.L., Kotagal S., Picchietti D. 1001 intravenous ferric carboxymaltose for restless legs syndrome in children and adolescents. Sleep 2020; 43 (1): A380. DOI: 10.1093/sleep/zsaa056.997
42. DelRosso L.M., Picchietti D.L., Ferri R. Comparison between oral ferrous sulfate and intravenous ferric carboxymaltose in children with restless sleep disorder. Sleep 2021; 44: zsaa155. DOI: 10.1093/sleep/zsaa155
43. Bevers N., van de Vijver E., Aliu A., Rezazadeh Ardabili A., Rosias P., Busari J., et al. P398 effect of intravenous versus oral iron therapy on physical fitness and haemoglobin in paediatric IBD patients with anaemia. J Crohns Colitis 2021; 15 (l): 407–8. DOI: 10.1093/ecco-jcc/jjab076.522
44. Korczowski B., Farrell C., Falone M., Blackman N., Rodgers T. Safety, pharmacokinetics, and pharmacodynamics of intravenous ferric carboxymaltose in children with iron deficiency anemia. Pediatr Res 2023; 94 (4): 1547–54. DOI: 10.1038/s41390-023-02644-9
